# UniFAHS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/unifahs

- Industry: Biotechnology
- Headquarters: Bangkok, Thailand
- Website: www.unifahs.com
- Total disclosed funding: $1.4M
- Latest round: Seed (Jan 4, 2024)
- Investors on record: 3

## About

Based in Thailand and founded in 2020, UniFAHS is a biotechnology business that uses phage technology to tackle antimicrobial resistance while also ensuring food safety and sustainability. In January 2024, UniFAHS raised USD 1.4 million in seed funding led by A2D Ventures with participation from ADB Ventures and InnoSpace Thailand. As of January 2024, Kitiya Vongkamjan is the Chief Executive Ofcier (CEO) of the company.

UniFAHS uses phage technology for sustainable and safe food production, tackling global issues such as antimicrobial resistance (AMR). The company has a variety of phages that target important organisms connected to foodborne illnesses, such as Salmonella, E. coli, Listeria, and Vibrio. The company's focus extends to the animal industry, where they use phages to promote animal well-being. Furthermore, the company collaborates with partners including The University of Illinois, The University of Nottingham, Kasesart University, Newton Fund, Prince of Songkla University, and others.

The company plans to use the January 2024 funding to scale bacteriophage technology for sustainable agriculture.

## Funding rounds

- Seed, Jan 4, 2024, $1.4M — ADB Ventures, InnoSpace Thailand, A2D Ventures

## Investors

- ADB Ventures (https://capitalatlas.ai/funds/adb-ventures) — Seed
- InnoSpace Thailand (https://capitalatlas.ai/funds/innospace-thailand) — Seed
- A2D Ventures (https://capitalatlas.ai/funds/a2d-ventures) — Seed